Hydroxyurea (hydroxycarbamide) for sickle cell disease.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Cochrane Database of Systematic Reviews

• Publication date

  2017-04-20

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/14651858.CD002202.pub2PMID 28426137PMCID PMC6478259
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Natural history of sickle cell anemia in Saudi Arabs. A study of 270 subjects.

  2020cited by this paper
• Survival in adults with sickle cell disease in a high-income setting.

  2016cited by this paper
• Organ iron accumulation in chronically transfused children with sickle cell anaemia: baseline results from the TWiTCH trial

  2016cited by this paper
• Effects of hydroxyurea treatment for patients with hemoglobin SC disease

  2016cited by this paper
• Long-term treatment follow-up of children with sickle cell disease monitored with abnormal transcranial Doppler velocities.

  2016cited by this paper
• Novel Use of Hydroxyurea in an African Region With Malaria: Protocol for a Randomized Controlled Clinical Trial

  2016cited by this paper
• Therapeutic phlebotomy is safe in children with sickle cell anaemia and can be effective treatment for transfusional iron overload

  2015cited by this paper
• Sickle Cell Disease in Clinical Practice

  2015cited by this paper
• TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, randomised controlled trial

  2015cited by this paper
• Prevention of conversion to abnormal transcranial Doppler with hydroxyurea in sickle cell anemia: A Phase III international randomized clinical trial

  2015cited by this paper
• Liver iron concentration measurements by MRI in chronically transfused children with sickle cell anemia: baseline results from the TWiTCH trial

  2015cited by this paper
• Myelodysplastic syndrome with clonal cytogenetic abnormalities followed by fatal erythroid leukemia after 14 years of exposure to hydroxyurea for sickle cell anemia

  2015cited by this paper
• Hydroxycarbamide modulates components involved in the regulation of adenosine levels in blood cells from sickle-cell anemia patients

  2014cited by this paper
• From Infancy to Adolescence: Fifteen Years of Continuous Treatment With Hydroxyurea in Sickle Cell Anemia

  2014cited by this paper
• Sickle cell disease: a neglected chronic disease of increasing global health importance

  2014cited by this paper
• Effects of Chronic Transfusion Therapy on MRI and MRA in Children with Sickle Cell Anemia at Risk for Primary Stroke: Baseline Imaging from the Twitch Trial

  2014cited by this paper
• Effects of Chronic Transfusion Therapy on transcranial Doppler Ultrasonography Velocities in Children with Sickle Cell Anemia at Risk for Primary Stroke: Baseline Findings from the Twitch Trial

  2014cited by this paper
• Immunologic Effects of Hydroxyurea in Sickle Cell Anemia

  2014cited by this paper
• Hydroxyurea and Growth in Young Children With Sickle Cell Disease

  2014cited by this paper
• Mortality Rates and Age at Death from Sickle Cell Disease: U.S., 1979–2005

  2013cited by this paper
• Efficacy and safety of deferasirox compared with deferoxamine in sickle cell disease: Two‐year results including pharmacokinetics and concomitant hydroxyurea

  2013cited by this paper
• Pain and other non‐neurological adverse events in children with sickle cell anemia and previous stroke who received hydroxyurea and phlebotomy or chronic transfusions and chelation: Results from the SWiTCH clinical trial

  2013cited by this paper
• Extrahepatic Iron Deposition In Chronically Transfused Children With Sickle Cell Anemia – Baseline Findings From The Twitch Trial

  2013cited by this paper
• Comparison of hematologic measurements between local and central laboratories: data from the BABY HUG trial.

  2013cited by this paper
• Emerging Science of Hydroxyurea Therapy for Pediatric Sickle Cell Disease

  2013cited by this paper
• Developmental Function in Toddlers With Sickle Cell Anemia

  2013cited by this paper
• Global epidemiology of sickle haemoglobin in neonates: a contemporary geostatistical model-based map and population estimates

  2013cited by this paper
• Hydroxyurea Is Associated With Lower Costs of Care of Young Children With Sickle Cell Anemia

  2013cited by this paper
• Genetic modifiers of sickle cell anemia in the BABY HUG cohort: influence on laboratory and clinical phenotypes

  2013cited by this paper
• Low Fixed-Dose Hydroxyurea in Severely Affected Indian Children with Sickle Cell Disease

  2012cited by this paper
• Genotoxicity associated with hydroxyurea exposure in infants with sickle cell anemia: Results from the BABY‐HUG phase III clinical trial

  2012cited by this paper
• Development of Myelodysplastic Syndrome and Acute Myeloid Leukemia 15 Years after Hydroxyurea Use in a Patient with Sickle Cell Anemia

  2012cited by this paper
• Management of an acute painful sickle cell episode in hospital: summary of NICE guidance

  2012cited by this paper
• Genetic Predictors of Hemoglobin F Response to Hydroxyurea in Sickle Cell Anemia

  2012cited by this paper
• Influence of severity of anemia on clinical findings in infants with sickle cell anemia: Analyses from the BABY HUG study

  2012cited by this paper
• Impact of hydroxyurea on clinical events in the BABY HUG trial.

  2012cited by this paper
• Stroke With Transfusions Changing to Hydroxyurea (SWiTCH).

  2012cited by this paper
• Massive accidental overdose of hydroxyurea in a young child with sickle cell anemia

  2012cited by this paper
• Chronic transfusion practices for prevention of primary stroke in children with sickle cell anemia and abnormal TCD velocities

  2012cited by this paper
• Effects of Hydroxyurea (HU) On Lymphocyte Subsets and the Immune Response to Pneumococcal, Measles, Mumps and Rubella Vaccination in the Pediatric Hydroxyurea Phase III Clinical Trial - BABY HUG - (ClinicalTrials.gov Identifier: NCT00006400)

  2012cited by this paper
• Effect of hydroxyurea treatment on renal function parameters: Results from the multi‐center placebo‐controlled BABY HUG clinical trial for infants with sickle cell anemia

  2012cited by this paper
• Transfusional iron overload in children with sickle cell anemia on chronic transfusion therapy for secondary stroke prevention

  2012cited by this paper
• Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG).

  2011cited by this paper
• A Randomized Phase II Study Evaluating the Efficacy and Safety of Deferasirox Versus Deferoxamine in Patients with Sickle Cell Disease (SCD): 2-Year Results Including Pharmacokinetics (PK) and Safety of Deferasirox with Concomitant Hydroxyurea Therapy

  2011cited by this paper
• Mortality and causes of death in children with sickle cell disease in the Netherlands, before the introduction of neonatal screening

  2011cited by this paper
• Sickle Cell Disease in Africa

  2011cited by this paper
• Fetal Hemoglobin Response to Hydroxyurea in Yemeni Sickle Cell Disease Patients

  2011cited by this paper
• Abdominal ultrasound with scintigraphic and clinical correlates in infants with sickle cell anemia: baseline data from the BABY HUG trial.

  2011cited by this paper
• The effects of hydroxycarbamide and magnesium on haemoglobin SC disease: results of the multi‐centre CHAMPS trial

  2011cited by this paper
• The association between hydroxyurea treatment and pain intensity, analgesic use, and utilization in ambulatory sickle cell anemia patients.

  2011cited by this paper
• Chromosome damage and repair in children with sickle cell anaemia and long‐term hydroxycarbamide exposure

  2011cited by this paper
• Stroke with transfusions changing to hydroxyurea (SWiTCH): A phase III randomized clinical trial for treatment of children with sickle cell anemia, stroke, and iron overload

  2011cited by this paper
• Hydroxyurea and acute painful crises in sickle cell anemia: effects on hospital length of stay and opioid utilization during hospitalization, outpatient acute care contacts, and at home.

  2010cited by this paper
• The impact of hydroxyurea on career and employment of patients with sickle cell anemia.

  2010cited by this paper
• Population estimates of sickle cell disease in the U.S.

  2010cited by this paper
• Renal function in infants with sickle cell anemia: baseline data from the BABY HUG trial.

  2010cited by this paper
• The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: results of a 17-year, single-center trial (LaSHS).

  2010cited by this paper
• How I use hydroxyurea to treat young patients with sickle cell anemia.

  2010cited by this paper
• The risks and benefits of long‐term use of hydroxyurea in sickle cell anemia: A 17.5 year follow‐up

  2010cited by this paper
• Recruitment of infants with sickle cell anemia to a Phase III trial: data from the BABY HUG study.

  2010cited by this paper
• The pediatric hydroxyurea phase III clinical trial (BABY HUG): Challenges of study design

  2010cited by this paper
• Urine concentrating ability in infants with sickle cell disease: Baseline data from the phase III trial of hydroxyurea (BABY HUG)

  2010cited by this paper
• Influence of Hemoglobin Level on Clinical Findings In Infants with Sickle Cell Anemia: Data From BABY HUG

  2010cited by this paper
• Stroke with Transfusions Changing to Hydroxyurea (SWiTCH): A Phase 3 Randomized Clinical Trial for Treatment of Children with Sickle Cell Anemia, Previous Stroke, and Iron Overload

  2010cited by this paper
• Definition of the Responder to Hydroxyurea Therapy: Revisited.

  2009cited by this paper
• Adherence to study medication and visits: Data from the BABY HUG trial

  2009cited by this paper
• Meta-analysis of individual patient data versus aggregate data from longitudinal clinical trials

  2009cited by this paper
• Transcranial doppler ultrasonography (TCD) in infants with sickle cell anemia: Baseline data from the BABY HUG trial

  2009cited by this paper
• Patterns of Analgesic Utilization in the Multicenter Study of Hydroxyurea (MSH).

  2009cited by this paper
• Impact of Hydroxyurea On Employment Among Patients with Sickle Cell Anemia.

  2009cited by this paper
• Developmental Outcomes of Offspring of Adults Treated with Hydroxyurea in the Multicenter Study of Hydroxyurea.

  2009cited by this paper
• The number of people with sickle‐cell disease in the United States: national and state estimates

  2009cited by this paper
• Exposure to hydroxyurea and pregnancy outcomes in patients with sickle cell anemia.

  2009cited by this paper
• Sickle Cell Genetic Markers: Geographic Distribution and Relation to Pain Outcomes in Multicenter Study of Hydroxyurea in Sickle Cell Anemia.

  2009cited by this paper
• Hydroxyurea in children with sickle cell disease: Practice patterns and barriers to utilization

  2009cited by this paper
• Effects of Hydroxyurea (HU) and Magnesium Pidolate (Mg) in Hemoglobin SC Disease (HbSC): the “CHAMPS” Trial.

  2009cited by this paper
• Spleen Function in Infants with Sickle Cell Anemia: Baseline Data from the BABY HUG Trial.

  2008cited by this paper
• Serum Cystatin-C Levels in Infants with Sickle Cell Anemia: Baseline Data from the BABY HUG Trial

  2008cited by this paper
• NTP-CERHR monograph on the potential human reproductive and developmental effects of hydroxyurea.

  2008cited by this paper
• Improved survival of children and adolescents with sickle cell disease.

  2008cited by this paper
• Urine Concentrating Ability in Infants with Sickle Cell Anemia: Baseline Data from the BABY HUG Trial.

  2008cited by this paper
• Transcranial Doppler (TCD) Ultrasonography in Infants with Sickle Cell Anemia: Baseline Data from the BABY HUG Trial.

  2008cited by this paper
• Chapter 8: Assessing risk of bias in included studies

  2008cited by this paper
• Neurodevelopment in Infants with Sickle Cell Anemia: Baseline Data from the Baby HUG Trial

  2008cited by this paper
• Hydroxyurea for Sickle Cell Disease: A Systematic Review for Efficacy and Toxicity in Children

  2008cited by this paper
• Study Drug and Visit Adherence: Data from the BABY HUG Trial.

  2008cited by this paper
• A common pathway mediated through Toll-like receptors leads to T- and natural killer-cell immunosuppression.

  2008cited by this paper
• Recruitment of Infants with Sickle Cell Anemia to a Phase III Trial:Data from the BABY HUG Study.

  2008cited by this paper
• Influence of sickle cell disease and treatment with hydroxyurea on sperm parameters and fertility of human males

  2008cited by this paper
• Clinical outcomes in children with sickle cell disease living in England: a neonatal cohort in East London.

  2007cited by this paper
• Time Series Analysis of the Pain Diary Data Obtained during the Multicenter Study for Hydroxyurea (MSH) Clinical Trial.

  2006cited by this paper
• Pharmacokinetics of hydroxyurea 1,000 mg coated breakable tablets and 500 mg capsules in pediatric and adult patients with sickle cell disease.

  2006cited by this paper
• Hydroxyurea and sickle cell anemia: effect on quality of life

  2006cited by this paper
• Stroke Prevention Trial in Sickle Cell Anemia (STOP): extended follow-up and final results.

  2006cited by this paper
• Academic Community Standards for Chronic Transfusion Therapy in Children with Sickle Cell Anemia and Stroke.

  2006cited by this paper
• Meta-analysis of individual patient data from randomized trials: a review of methods used in practice

  2005cited by this paper
• Stem cell plasticity: time for a reappraisal?

  2005cited by this paper
• TCD in Infants: A Report from the BABY HUG Trial.

  2005cited by this paper
• Pharmacokinetics of Hydroxyurea in Young Children with Sickle Cell Anemia: A Report from the BABY HUG Trial.

  2005cited by this paper
• Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease.

  2004cited by this paper

• Hydrogen bonding in hydroxyurea: A Raman and density functional theory study

  2026cites this paper
• Improving Vaso-occlusive Pain Through Standardized Sickle Cell Pain-Treatment Guidelines

  2026cites this paper
• Preventive health practices and clinical outcomes in sickle cell disease: insights from the 2022 world sickle cell day celebration

  2026cites this paper
• MeMAGEN: A Phase IIa/IIb open‐label trial of memantine testing safety and tolerability in sickle cell patients

  2026cites this paper
• In Silico Post-screening of Anti-polymerization Agents to Treat Sickle Cell Disease

  2025cites this paper
• Impact of sickle cell anaemia on reproductive health: a narrative review

  2025cites this paper
• Exploring Barriers and Strategies for Hydroxyurea Uptake Using the CFIR–ERIC Framework: A Qualitative Study of Sickle Cell Disease in India.

  2025cites this paper
• Emergency department utilization patterns in adults living with sickle cell disease

  2025cites this paper
• UHRF2 as a genetic correlate of hospitalization in sickle cell disease

  2025cites this paper
• Caregivers’ beliefs about hydroxyurea influence its usage among children with sickle cell disease: a cross-sectional study in Dar-es-Salaam, Tanzania

  2025cites this paper
• Health-Related Quality of Life Measurement in Adults With Sickle Cell Disease in Steady State: Experience of One French Reference Center

  2025cites this paper
• Acute chest syndrome (ACS) in sickle cell disease (SCD): pathogenesis and pharmacotherapies in early clinical development

  2025cites this paper
• Updating the Brazilian clinical practice guidelines for sickle cell disease: Recommendations and development process

  2025cites this paper
• Association between sickle cell disease and autoimmune diseases in Saudi population: a single center study

  2025cites this paper
• Level of Healthcare Facility and Psychosocial Factors Influence Perceived Self-Efficacy for Appropriate Use of Hydroxyurea: Experience from Caregivers of Children with Sickle Cell Disease in Tanzania

  2025cites this paper
• Orphan Nuclear Receptors TR2 and TR4 in Erythropoiesis: From Mechanisms to Therapies

  2025cites this paper
• Hydroxyurea - Pragmatic Reduction In Mortality and Economic burden (H-PRIME): A 2x2x2 factorial randomised open-label trial investigating practical approaches to the treatment of sickle cell disease at four sites in Eastern Uganda

  2025cites this paper
• Human Genome Editing and Sickle Cell Disease in Canada: Urgent and Unresolved Ethical Considerations

  2025influential citation
• DFT study of (6,0) boron nitride nanotube as a drug delivery system for 5-fluorouracil and hydroxyurea

  2025cites this paper
• CureSCi Metadata Catalog—Finding and harmonizing studies for secondary analysis of hydroxyurea discontinuation in sickle cell disease

  2025influential citation
• A review on disease modifying pharmacologic therapies for sickle cell disease

  2025cites this paper
• Comparative valuation of longstanding and novel treatments for sickle cell disease: a multinational MCDA study

  2025cites this paper
• A Rational Approach to Pharmacotherapy in Pregnancy

  2025cites this paper
• Unravelling the Immunological Enigma of Sickle Cell Disease: Current Understanding and Future Directions

  2025cites this paper
• Clinical Complications, Mortality, and Healthcare Resource Utilization of Patients with Sickle Cell Disease with Recurrent Vaso-Occlusive Crises in Ontario, Canada: A Retrospective Cohort Study

  2025cites this paper
• A novel composition of endogenous metabolic modulators improves red blood cell properties in sickle cell disease

  2024cites this paper
• Targeting P-selectin and interleukin-1b in mice with sickle cell disease: effects on vaso-occlusion, liver injury and organ iron deposition

  2024cites this paper
• Impact of hydroxycarbamide treatment on the whole‐blood transcriptome in sickle cell disease

  2024cites this paper
• Exploring Novel Strategies to Alleviate Symptoms of β-Globinopathies: Examining the Potential Role of Embryonic ε-globin Induction.

  2024cites this paper
• Respiratory management of acute chest syndrome in children with sickle cell disease

  2024cites this paper
• Hydroxyurea in the sickle cell disease modern era

  2024cites this paper
• A cellular reporter system to evaluate endogenous fetal hemoglobin induction and screen for therapeutic compounds

  2024cites this paper
• Splenic complications in pediatric sickle cell disease: A retrospective cohort review

  2024cites this paper
• Utilization and Perceptions of Hydroxyurea Therapy Among Adult Patients With Sickle Cell Disease in Al Ahsa, Saudi Arabia: A Cross-Sectional Study

  2024cites this paper
• Hydroxyurea maintains working memory function in pediatric sickle cell disease

  2024cites this paper
• Feasibility of a clinic‐based, multicomponent hydroxyurea adherence intervention for adolescents and young adults with sickle cell disease

  2024cites this paper
• Effects of hydroxyurea on fertility in male and female sickle cell disease patients. A systemic review and meta-analysis

  2024cites this paper
• Reviewing the impact of hydroxyurea on DNA methylation and its potential clinical implications in sickle cell disease

  2024cites this paper
• Hydration of N-Hydroxyurea from Ab Initio Molecular Dynamics Simulations

  2024cites this paper
• Cost-effectiveness of l-glutamine versus crizanlizumab for adults with sickle cell disease: model focused on reducing pain episode costs from Qatar’s healthcare perspective

  2024cites this paper
• Factors associated with adverse outcome among children with sickle cell disease admitted to the pediatric intensive care unit: an observational cohort

  2024cites this paper
• Sickle Eye Project: a cross-sectional, non-interventional study of the prevalence of visual impairment due to sickle cell retinopathy and maculopathy in the UK

  2024influential citation
• Angiopoietin-2 is associated with sickle cell complications, including stroke risk, and decreases with hydroxyurea therapy

  2024cites this paper
• Ethical and Clinical Considerations in the Use of Hydroxyurea in Pregnant Women with Sickle Cell Disease

  2024cites this paper
• Impact of temporary and involuntary suppression of hydroxyurea treatment on hematological and clinical parameters in patients with sickle cell disease

  2024cites this paper
• The value-based price of transformative gene therapy for sickle cell disease: a modeling analysis

  2024cites this paper
• Sickle Cell Disease Update: New Treatments and Challenging Nutritional Interventions

  2024cites this paper
• Adherence to Hydroxyurea and Patients’ Perceptions of Sickle Cell Disease and Hydroxyurea: A Cross-Sectional Study

  2024cites this paper
• Impact of Hydroxyurea to Treat Haematological Disorders on Male Fertility: Two Case Reports and a Systematic Review

  2024cites this paper
• Caregivers’ Perceived Threat Of Sickle Cell Disease Complications And Its Association With Hydroxyurea Use Among Children With Sickle Cell Disease In Dar Es Salaam, Tanzania

  2024cites this paper
• BCL11A +58/+55 enhancer-editing facilitates HSPC engraftment and HbF induction in rhesus macaques conditioned with a CD45 antibody-drug conjugate.

  2024cites this paper
• Stroke-Related Outcomes in Moyamoya Disease Compared to Moyamoya Syndromes: A Propensity-Matched Analysis.

  2024cites this paper
• Assessing a BN-Doped Graphene for the Drug Delivery of Hydroxyurea Anticancer

  2023cites this paper
• Heteroatom (B, N, P, and S)-Doped Cyclodextrin as a Hydroxyurea (HU) Drug Nanocarrier: A Computational Approach

  2023cites this paper
• Allogeneic hematopoietic stem cell transplantation to cure sickle cell disease: A review

  2023influential citation
• Transcranial Doppler Ultrasonography-Related Research in the Caribbean Region

  2023cites this paper
• Bach1 inhibitor HPP-D mediates γ-globin gene activation in sickle erythroid progenitors.

  2023cites this paper
• Case 37-2023: A 29-Year-Old Man with Sickle Cell Disease and Right Hip Pain.

  2023cites this paper
• Hydroxyurea inhibits ERAD-L independently of S-phase arrest in budding yeast

  2023cites this paper
• Defining curative endpoints for sickle cell disease in the era of gene therapy and gene editing

  2023cites this paper
• Hydroxyurea maintains working memory function in pediatric sickle cell disease

  2023cites this paper
• Red Blood Cells as Therapeutic Target to Treat Sickle Cell Disease

  2023cites this paper
• Precision, integrative medicine for pain management in sickle cell disease

  2023cites this paper
• Fatty acid nitroalkenes – Multi-target agents for the treatment of sickle cell disease

  2023cites this paper
• Metabolic signatures of cardiorenal dysfunction in plasma from sickle cell patients, as a function of therapeutic transfusion and hydroxyurea treatment

  2023cites this paper
• Pethidine-Related Neurotoxicity in Pediatric Sickle Cell Disease: A Systematic Review

  2023cites this paper
• A multilevel mHealth intervention boosts adherence to hydroxyurea in individuals with sickle cell disease

  2023cites this paper
• Comment on: Intraindividual pain variability metrics for youth with sickle cell disease: Relations to health outcomes

  2023cites this paper
• Efficacy, safety, and pharmacokinetics of a new, ready-to-use, liquid hydroxyurea in children with sickle cell anemia

  2023cites this paper
• Evaluation of bioactive compounds as antimicrobial and antidiabetic agent from the crude extract of Heliotropium curassavicum L.

  2023cites this paper
• Efficacy of Hydroxyurea in Transfusion-Dependent Major β-Thalassemia Patients: A Meta-Analysis

  2023cites this paper
• Managing the Cerebrovascular Complications of Sickle Cell Disease: Current Perspectives

  2023cites this paper
• Factors associated with health-related quality of life in children with sickle cell disease.

  2023cites this paper
• [Lung manifestations of sickle-cell disease].

  2023cites this paper
• Metabolic signatures of cardiorenal dysfunction in plasma from sickle cell patients as a function of therapeutic transfusion and hydroxyurea treatment

  2023cites this paper
• Managing Sickle Cell Disease in Patients for Whom Blood Transfusion Is Not an Option.

  2022cites this paper
• Repurposing of Hydroxyurea Against COVID-19: A Promising Immunomodulatory Role

  2022cites this paper
• P122: DEEP LEARNING-BASED ALGORITHM FOR AUTOMATIC SPLEEN LENGTH MEASUREMENT

  2022cites this paper
• Clinical challenges to the concept of ectogestation

  2022cites this paper
• A randomised double-blind placebo-controlled clinical trial of oral hydroxyurea for transfusion-dependent β-thalassaemia

  2022cites this paper
• Higher hydroxyurea adherence among young adults with sickle cell disease compared to children and adolescents

  2022cites this paper
• Testicular Tissue Banking for Fertility Preservation in Young Boys: Which Patients Should Be Included?

  2022cites this paper
• Treatment of sickle cell disease: Beyond hydroxyurea

  2022cites this paper
• What can work and how? An overview of evidence-based interventions and delivery strategies to support health and human development from before conception to 20 years.

  2022cites this paper
• Influence of hydroxyurea on the severity of acute chest syndrome in patients with sickle cell disease.

  2022cites this paper
• Accuracy of online medical information: the case of social media in sickle cell disease

  2022cites this paper
• Sickle Cell Disease, a Review

  2022cites this paper
• Sickle Cell Disease: A Review.

  2022cites this paper
• Recent advances in “sickle and niche” research - Tribute to Dr. Paul S Frenette -

  2022cites this paper
• Health-Related Quality of Life and Adherence to Hydroxyurea and Other Disease-Modifying Therapies among Individuals with Sickle Cell Disease: A Systematic Review

  2022cites this paper
• Exercise Capacity and Biomarkers Among Children and Adolescents With Sickle Cell Disease.

  2022cites this paper
• Effective therapies for sickle cell disease: are we there yet?

  2022cites this paper
• Hydroxyurea (hydroxycarbamide) for sickle cell disease.

  2022cites this paper
• Diverse Approaches to Gene Therapy of Sickle Cell Disease.

  2022cites this paper
• Prevalence of people with sickle cell disease and leg ulcers in Brazil: Socioeconomic and clinical overview

  2022cites this paper
• Krüppel-Like Factor 1: A Pivotal Gene Regulator in Erythropoiesis

  2022cites this paper
• Sickle Cell Disease in Children and Adolescents: A Review of the Historical, Clinical, and Public Health Perspective of Sub-Saharan Africa and Beyond

  2022cites this paper
• O que sabemos sobre aptidão física, atividade física e exercícios para jovens com doença falciforme? Um estudo de revisão

  2022cites this paper
• Incidence of cancer and related deaths in hemoglobinopathies: A follow‐up of 4631 patients between 1970 and 2021

  2022cites this paper
• Utilization of Hydroxyurea Among Patients Diagnosed with Sickle Cell Disease in Jazan, Saudi Arabia

  2022cites this paper